Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$71.15
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BMY Avg Daily Volume: 6,233,100
Last Update: 05/05/16 - 4:01 PM EDT
Volume: 0
YTD Performance: 3.43%
Open: $0.00
Previous Close: $71.15
52 Week Range: $51.82 - $73.06
Oustanding Shares: 1,669,307,273
Market Cap: 118,153,568,783
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 6
Moderate Buy 1 1 1 1
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 2 1 0 0
Mean Rec. 2.28 2.18 1.96 1.96
Latest Dividend: 0.38
Latest Dividend Yield: 2.15%
Dividend Ex-Date: 03/30/16
Price Earnings Ratio: 35.21
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
35.21 75.90 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.32% 9.41% 76.99%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.30 -0.10 -0.02
Net Income -19.60 -0.30 -0.13
EPS -22.30 -0.20 -0.07
Earnings for BMY:
EBITDA 2.27B
Revenue 16.56B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.64 $0.63 $2.60 $3.34
Number of Analysts 8 6 10 10
High Estimate $0.68 $0.69 $2.71 $3.68
Low Estimate $0.57 $0.60 $2.50 $3.01
Prior Year $0.53 $0.39 $2.01 $2.60
Growth Rate (Year over Year) 20.05% 62.39% 29.35% 28.50%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Bullish
May 05, 2016 | 6:52 AM EDT
Shares of BMY now seen reaching $75, according to Jefferies. Estimates also increased, givne a faster expected ramp for the Opdivo mono...
Update
May 03, 2016 | 7:04 AM EDT
BMY - Bristol-Myers Squibb Co Annual Shareholders Meeting - 10AM
It's mighty tough to put a multiple on a declining business.
The drug maker is approaching overbought territory, but is set up well for more upside.
We recently got a golden cross of the 50-day and 200-day averages.
Bearish
Apr 07, 2016 | 7:47 AM EDT
Coverage of BMY was started with a Sell rating, Societe Generale said. $48 price target. Estimates also below consensus, given lower ex...
The pharmaceutical company's stock is likely to weaken further if it declines below $61 and $60 in the days ahead.
The group rallied yesterday, but it's still not out of the woods.

Columnist Conversations

$550 million to buy market on close.
breadth is weak and fear is rising in front NFP. we will add protection. BOUGHT SPY MAY 206 PUT AT 2.97 BOUGHT...
Market has lost early but slight gains, and now sports small losses. Equities don't seem to have much directi...
Is to find Yale Liebowitz's photo (he was Pablo's best friend in first grade) in The Donald First Grade photo!...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.